Farhan Damani

AI x drug discovery. Currently working on something new. Previously @Dyno_Tx @Princeton @JohnsHopkins

[Sam Sinai @samsinai]

We’ve now licensed our second AI-designed capsid, this time targeting muscle (after CNS). The only benchmark that counts is whether it works in the body. Doing it again, in a different organ, shows the power of our platform. Huge congrats to the team and excited to see this help patients.

[Zavain Dar @zavaindar]

new drop from @_DimensionCap x @SimonDBarnett

[Elliot Hershberg @ElliotHershberg]

Hub-and-Spoke Biotechs: Nimbus Therapeutics

I wrote about how Nimbus's fundamental business model innovation enabled them to make blockbuster drug deals—without selling their entire company.

Here's how they built an "evergreen" R&D engine.
https://t.co/3FQt7IYxTM

[Sam Sinai @samsinai]

On behalf of @Dyno_Tx's ML team, we are so excited for the work we are going to do with @NVIDIAAI. Special thanks to @ReneeYao1 , @anthonycosta (among many others), and of course the visionary Jensen Huang who sees the size of the opportunity at the intersection of #AI and biology. 🚀

[Sam Sinai @samsinai]

David Brookes* took the main stage @SynBioBeta and gave a brief overview of our collective work @Dyno_Tx today, showing (1) How we can venture deep into sequence space with our AI models, away from the evolutionary trajectory, finding protein sequences that are helpful to humans

[Farhan Damani @FarhanD7]

The YouTube link can be found here: https://t.co/3mcgNNnkeC

[Farhan Damani @FarhanD7]

Tomorrow I will be giving a talk at #MLCB2023 focused on our recent work at @Dyno_Tx studying distribution shift in ML-guided sequence design. The talk will be live-streamed on YouTube. Our team will also be presenting two posters -- see below for details!

[Dyno Therapeutics, Inc. @Dyno_Tx]

Dyno is heading to #MLCB2023 this Thursday + Friday to share our latest advancements in Machine Learning methods for AAV design and gene therapy! On Nov 30th from 2:35-2:55 PST we’re giving a talk, then at 4:50-6:30 PST we’ll be presenting two posters. Be sure to catch us there!

[Schaefer Lab @lab_schaefer]

Amazing presentation by @hayleystrasburg from @lab_schaefer at @gliameeting euroglia meeting in Berlin. Could not be more proud.

[Dyno Therapeutics, Inc. @Dyno_Tx]

Today at #ASGCT23, we shared data on a breakthrough CNS-targeted AAV capsid that dramatically improves pan-brain neuronal transduction & liver detargeting in NHPs at a low IV dose. Learn more at https://t.co/fDNdRchpy4

[Dyno Therapeutics, Inc. @Dyno_Tx]

Interested in learning more about Dyno’s AAV capsids with >100X improved transduction to retina and CNS? Schedule a 1:1 w/ us at BIO 2023 through the One-on-One Partnering portal - see you next week in Boston! #BIO2023

[Sam Sinai @samsinai]

1/ [Tweetorial 🧵] Excited to share some theoretical advances from our team @Dyno_Tx led by David H Brookes, building on his graduate work on exploiting the sparsity of fitness functions in the Walsh-Hadamard/Fourier space for learning and design. https://t.co/rPKQRx1koK

[Farhan Damani @FarhanD7]

Excited to be at NeurIPS this year along with many colleagues from @Dyno_Tx! Looking forward to chatting with people about ML for sequence design, model-based optimization, and offline RL.

[Farhan Damani @FarhanD7]

At @Dyno_Tx we are working on building the future of gene therapy with ML guided design. Come work with us! We have lots of open positions in ML and engineering.

[Sam Sinai @samsinai]

We have plenty of engineering positions open. We don't sell ads. We work on difficult & exciting machine learning problems. We have really unique data and talented people. If we succeed, millions of people would see a huge improvement on their quality of life. Come work with us!

[Dyno Therapeutics, Inc. @Dyno_Tx]

Dyno announces our partnership with Astellas, valued at up to $1.6 billion, for developing next-gen AAV gene therapy vectors for skeletal and cardiac muscle diseases. https://t.co/5puTMEuG9T

[Stephen Malina @an1lam]

We (@Dyno_Tx) just published post 1/3 in our new introduction to AAV blog post series. This post covers AAV biology with the goal of setting the stage for post 2 (on AAV engineering) and post 3 (on Dyno's workflow).

https://t.co/SpGGgfYHmc

[Jorge Conde @JorgeCondeBio]

Can we safely deliver better gene therapies for more diseases? Founder/CEO @ekelsic joins me to discuss how @Dyno_Tx is using AI to reshape the gene therapy landscape 🧬

w/ @vintweeta @vijaypande @pmarca @julesyoo @a16z
Mon May 10 5PM PDT @joinclubhouse. https://t.co/Akv7YBXU4D

[Eric Kelsic (he/him) @ekelsic]

@Dyno_Tx 's $100M Series A led by @a16z, welcome to our team of #AAViators @JorgeCondeBio + @cascapital , @GVteam, @obviousvc & @Lux_Capital. We will use these funds to solve in vivo gene delivery towards helping more patients benefit from #genetherapy!

[Farhan Damani @FarhanD7]

I joined Dyno because of their deep-seated belief in ML-guided design as a powerful platform to help solve the delivery problem in gene therapy. A year later and we're making rapid progress. Exciting times ahead!

[Dyno Therapeutics, Inc. @Dyno_Tx]

Dyno Therapeutics Closes $100 Million Series A Financing Led by Andreessen Horowitz to Accelerate AI‑powered Gene Therapy Platform.

https://t.co/xPLEy76viX

[Sam Sinai @samsinai]

1/As a side-kick to our bigger supervised modeling project that recently came out, we also tried using the VAE model for proteins I had worked on in 2017 to design 3750 sequences. Here are the results: https://t.co/Cl7U2mq96G

[Farhan Damani @FarhanD7]

@an1lam @Dyno_Tx @samsinai @opetanypaszeko @elooopy Wohoo!! Welcome, @an1lam! Excited to work together!